Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-defensin 126 (DEFB126) is a highly glycosylated, secreted, cysteine-rich cationic polypeptide belonging to the beta-defensin family, which are a subgroup of antimicrobial peptides involved in the innate immune response to microorganisms[1][3][5]. DEFB126 is produced predominantly in the male reproductive tract and coats sperm, conferring a substantial negative surface charge due to O-linked glycosylation. This function facilitates sperm passage through cervical mucus and protects sperm from recognition and attack by the female immune system[2][3][5]. The protein is also involved in the binding of sperm to oviductal epithelial cells to form a reservoir until ovulation, and its removal from sperm is necessary for successful fertilization[3][5]. Variants in DEFB126 can impair fertility, and the protein also has documented antimicrobial roles and may inhibit inflammation[1][3]. No drugs targeting DEFB126 have been described, and it is not considered a therapeutic target or receptor in current clinical use[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-defensin 126 (DEFB126).